Search Results - "Subegdjo, S."

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression by Aguilar, E.J., Ricciuti, B., Gainor, J.F., Kehl, K.L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L.M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R.M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K.C., Carter, B.W., Heymach, J.V., Altan, M., Hellmann, M.D., Awad, M.M.

“…In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor…”
Get full text

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression by Aguilar, E J, Ricciuti, B, Gainor, J F, Kehl, K L, Kravets, S, Dahlberg, S, Nishino, M, Sholl, L M, Adeni, A, Subegdjo, S, Khosrowjerdi, S, Peterson, R M, Digumarthy, S, Liu, C, Sauter, J, Rizvi, H, Arbour, K C, Carter, B W, Heymach, J V, Altan, M, Hellmann, M D, Awad, M M

“…In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor…”
Get full text